A detailed history of M&T Bank Corp transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 399,548 shares of PMVP stock, worth $643,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
399,548
Previous 399,548 -0.0%
Holding current value
$643,272
Previous $595,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.44 - $1.69 $203,132 - $238,398
141,064 Added 54.57%
399,548 $595,000
Q1 2024

May 07, 2024

BUY
$1.51 - $3.12 $91,811 - $189,702
60,802 Added 30.76%
258,484 $439,000
Q4 2023

Feb 06, 2024

BUY
$1.23 - $6.6 $243,148 - $1.3 Million
197,682 New
197,682 $612,000
Q1 2023

May 11, 2023

BUY
$4.77 - $9.16 $17,515 - $33,635
3,672 Added 8.87%
45,090 $215,000
Q4 2022

Feb 13, 2023

BUY
$8.17 - $12.95 $168,481 - $267,054
20,622 Added 99.16%
41,418 $360,000
Q4 2022

Feb 13, 2023

SELL
$8.17 - $12.95 $112,484 - $178,295
-13,768 Reduced 39.83%
20,796 $180,000
Q3 2022

Nov 14, 2022

SELL
$11.4 - $17.18 $3,990 - $6,013
-350 Reduced 1.0%
34,564 $412,000
Q2 2022

Aug 05, 2022

BUY
$9.23 - $22.43 $231,959 - $563,688
25,131 Added 256.88%
34,914 $498,000
Q1 2022

May 09, 2022

BUY
$14.86 - $23.55 $12,066 - $19,122
812 Added 9.05%
9,783 $204,000
Q4 2021

Feb 07, 2022

BUY
$19.99 - $30.24 $9,775 - $14,787
489 Added 5.77%
8,971 $207,000
Q3 2021

Oct 28, 2021

BUY
$26.84 - $36.58 $227,656 - $310,271
8,482 New
8,482 $253,000
Q1 2021

May 06, 2021

SELL
$30.66 - $49.5 $138,613 - $223,789
-4,521 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$31.86 - $61.51 $144,039 - $278,086
4,521 New
4,521 $278,000

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $73.5M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.